Copyright ©The Author(s) 2016.
World J Gastroenterol. Aug 28, 2016; 22(32): 7175-7185
Published online Aug 28, 2016. doi: 10.3748/wjg.v22.i32.7175
Table 1 Studies reporting detection of circulating tumour cells in patients with pancreatic cancer
StudyCTC platformMarkersStage of diseaseTime of samplingNumber of patients, nCut-off for positivity per 7. 5 mL bloodCTCs detected, n
Zhang et al[16] 2014Immunocy-togeneticsCK, CD45, DAPI, CEP8All stagesPre-operative22416/22 (72.7%)
Rhim et al[17] 2014Micro-fluidic "GEM" ChipDAPI, CD45, CK, PDX-1All stagesDiagnosis11≥ 18/11 (73%)
Khoja et al[12] 2011CellSearch and ISETEpCAM, CK, vimentin, E-cadherinAll stagesDiagnosis or at time of diagnosis of progressive disease > 6 wk from therapy53≥ 121/53 (40%) using CellSearch
24/27 (93%) using ISET
Nagrath et al[18] 2013CTC-ChipCksMetastaticNot stated1537.5 (5/mL)15/15 (100%)
Allard et al[15] 2004CellSearchCK8, CK18, CK19MetastaticNot stated16≥ 16/16 ((38%)
Gall et al[19] 2013CellSearchEpCam, EGFRLocally advancedPre-treatment75≥ 14/75 (5%)
Ren et al[20] 2011Immuno-cyto-chemistryCA 19-9, CK8, CK18Locally advanced and metastaticPre- and post- treatment41≥ 133/41 (80.5%) pre-treatment and 12/41 (29.3%) post-treatment